Cerevel Therapeutics Holdings, Inc. Stock

Equities

CERE

US15678U1280

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
42.14 USD +1.30% Intraday chart for Cerevel Therapeutics Holdings, Inc. +0.31% -0.61%
Sales 2024 * - Sales 2025 * - Capitalization 7.65B
Net income 2024 * -456M Net income 2025 * -551M EV / Sales 2024 * -
Net cash position 2024 * 709M Net cash position 2025 * 690M EV / Sales 2025 * -
P/E ratio 2024 *
-16.9 x
P/E ratio 2025 *
-15 x
Employees 334
Yield 2024 *
-
Yield 2025 *
-
Free-Float 42.24%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Cerevel Therapeutics Holdings, Inc.

1 day+1.30%
1 week+0.31%
Current month-0.31%
1 month-0.99%
3 months-0.35%
6 months+85.56%
Current year-0.61%
More quotes
1 week
41.19
Extreme 41.185
42.21
1 month
41.19
Extreme 41.185
42.60
Current year
40.66
Extreme 40.66
43.59
1 year
19.59
Extreme 19.59
43.59
3 years
12.01
Extreme 12.01
46.16
5 years
9.00
Extreme 9
46.16
10 years
9.00
Extreme 9
46.16
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 23-06-11
Director of Finance/CFO 43 23-05-14
Chairman 63 18-11-30
Members of the board TitleAgeSince
Director/Board Member 63 19-05-31
Director/Board Member 61 18-08-31
Director/Board Member 66 20-12-03
More insiders
Date Price Change Volume
24-04-18 42.14 +1.30% 1,282,830
24-04-17 41.6 +0.70% 838,023
24-04-16 41.31 -0.94% 1,439,526
24-04-15 41.7 -0.36% 1,333,538
24-04-12 41.85 -0.38% 2,259,340

Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT

More quotes
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder and Parkinson’s disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinson’s disease.
Related indices
More about the company
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
42.14 USD
Average target price
44.78 USD
Spread / Average Target
+6.26%
Consensus